Characterization of multicellular breast tumor spheroids using image data-driven biophysical mathematical modeling

Haley J. Bowers1,2, Emily E. Fannin1, Alexandra Thomas3,4 & Jared A. Weis1,2,3

Multicellular tumor spheroid (MCTs) systems provide an in vitro cell culture model system which mimics many of the complexities of an in vivo solid tumor and tumor microenvironment, and are often used to study cancer cell growth and drug efficacy. Here, we present a coupled experimental-computational framework to estimate phenotypic growth and biophysical tumor microenvironment properties. This novel framework utilizes standard microscopy imaging of MCTs systems to drive a biophysical mathematical model of MCTs growth and mechanical interactions. By extending our previous in vivo mechanically-coupled reaction–diffusion modeling framework we developed a microscopy image processing framework capable of mechanistic characterization of MCTs systems. Using MDA-MB-231 breast cancer MCTS, we estimated biophysical parameters of cellular diffusion, rate of cellular proliferation, and cellular tractions forces. We found significant differences in these model-based biophysical parameters throughout the treatment time course between untreated and treated MCTS systems, whereas traditional size-based morphometric parameters were inconclusive. The proposed experimental-computational framework estimates mechanistic MCTs growth and invasion parameters with significant potential to assist in better and more precise assessment of in vitro drug efficacy through the development of computational analysis methodologies for three-dimensional cell culture systems to improve the development and evaluation of antineoplastic drugs.

Recent advances in precision medicine have improved the understanding of breast cancer and have led to the rapid emergence of new antineoplastic therapeutic agents for this patient group1,2. Molecularly targeted therapies have significantly increased therapeutic options with improved outcomes for many breast cancer molecular subtypes3. With the rapid emergence of new antineoplastic agents, and numerous drugs currently in development, there is an urgent unmet need for the generation of new technologies to provide informative evaluations of their efficiency throughout the stages of drug discovery and development. Traditionally, early stages of drug evaluation are performed using conventional 2D monolayer in vitro cell culture methods and are typically interpreted using drug dose-response curves based on cell viability and fit to a sigmoidal Hill-type model4. These observational monolayer drug evaluations have historically served as an essential model for investigating cancer cell behavior and identifying anti-cancer therapeutic efficiency, however these results cannot always be confirmed in preclinical animal trials or clinical trials5–8. Increasingly, monolayer cell cultures methods are insufficient for representation of in vivo solid tumors and their complex microenvironment and drug response behavior4. Efforts to evaluate drug efficacy for in vitro systems that more appropriately mimic in vivo conditions are being pursued to improve drug development. One example is through the use of three-dimensional (3D) multicellular tumor spheroids (MCTs) as they more closely resemble in vivo solid tumors compared to the much more simplified 2D culture systems, and bridge the gap between conventional monolayer cell culture methods and animal studies9,10. 3D MCTs invasion culture systems, consisting of a MCTS embedded within an extracellular matrix (ECM), provide a further enhanced biological model system which recapitulates several architectural and

1Department of Biomedical Engineering, Wake Forest School of Medicine, 575 N. Patterson Ave., Suite 530, Winston-Salem, NC 27101, USA. 2Virginia Tech – Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, VA, USA. 3Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, NC, USA. 4Department of Internal Medicine, Section of Hematology and Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA. *email: jweis@wakehealth.edu
surrounding environment, known as cellular traction forces, which has gained its popularity in cancer research. A highly studied mechanical interaction is the forces exerted by cancer cells on their microenvironment. A well-known example is the forces exerted by cancer cells on their ECM microenvironment, which can act to regulate cell behavior, function, and response to therapy. These mechanical interactions have been shown to be important in cancer cell invasion and metastasis. The triple-negative breast cancer cell line, MDA-MB-231, was used to establish the protocol.

Methods

Cell culture. The triple-negative breast cancer cell line, MDA-MB-231, was used to establish the protocol for spheroid generation and were obtained from ATCC, and were maintained in culture according to ATCC recommendations. The cells were labeled using a fluorescent histone H2B lentiviral vector (H2B-GFP, Addgene Plasmid #11680) to facilitate imaging analysis for identifying and estimating cell number. The modified cells were maintained in the same manner as their parental strains.

Multicellular tumor spheroid generation. MCTS were generated using the liquid overlay technique using CellCarrier spheroid ultra-low attachment 96-well microplates (Perkin Elmer). A total suspension volume of 200 μl containing 5,000 cells, cell-specific medium and 0.35 mg/ml concentration of Matrigel (Corning) was added to wells. To initiate spheroid formation, the microplate was centrifuged in a swinging bucket rotor at
300×g for 5 min. Cells were cultivated for 4 days to allow for spheroid self-assembly. Figure 1 shows a schematic describing the time course of MCTS generation.

**Invasion matrix.** A collagen solution made up of neutralized collagen type I (2.25 mg/ml, Corning) and is co-polymerized with 2 μm red fluorescent microsphere beads (FluoSpheres™ Carboxylate-Modified Microspheres, 580/605, 2 × 10^6 beads/ml) used to track extracellular matrix deformation. The spheroid generation plate was chilled on ice for 15 min to pre-chill wells. 200 μl of collagen solution was placed into a flat bottom 96-well ultra-microplate (Perkin Elmer, ULA CellCarrier-96 Ultra Microplates) with an optically-clear cyclic olefin bottom for optimal imaging acquisition. Once chilled, 25 μl containing the spheroid was removed from the spheroid generation plate and was added to the collagen solution (final collagen concentration of 2 mg/ml) and gently pipette mixed. Once all replicates were complete, the plate was allowed to polymerize at room temperature for 1 h followed by polymerization at 37°C for 1 h. Once completely polymerized, 100 μl of medium was overlaid in each well. A schematic representation of spheroid embedding into the invasion matrix is found in Fig. 1.

**Drug treatment.** At 24 h following embedding of MCTS in invasion matrix, spheroids were treated with nanoparticle albumin-bound paclitaxel (Abraxane) at a concentration of 400 nM. MCTS systems were exposed to the drug for 72 h. MCTS systems (treated and untreated) underwent media changes every 72 h.

**MCTS imaging and image processing.** While methodological descriptions for imaging and imaging processing steps follow, additional materials further describing and documenting the steps are available as supplementary materials. Briefly, time-lapse fluorescent microscopy imaging of both untreated and treated MCTS systems was used to characterize the changes in growth and dynamics. Imaging began 24 h after embedding MCTS in collagen and continued every 12 h for a total imaging time of 72 h. MCTS were imaged using a fully-automated time-lapse fluorescent microscope (EVOS FL Auto 2 Cell Imaging System, Invitrogen) with an on-stage incubator controlling CO₂ (5%), O₂, temperature (37°C), and humidity (EVOS Onstage Incubator, Invitrogen). Z-stack images of the MCTS and surrounding ECM were acquired with a 3 by 3 imaging grid using a 10X objective for an overall 500×500-micron field of view with pixel sizes of approximately 5 μm. Images were acquired in two co-registered fluorescence color channels, with the green channel (GFP) to image the MCTS and the red channel (Texas Red) to image the fluorescent microbeads. Figure 1 shows the workflow of data acquisi-
tion, image processing, and registration, the necessary steps to prepare the observational microscopy images to estimate cell number and deformation.

Microscopy images were compiled and stitched using a customized fully-automated tiling, stitching, registration, and segmentation software written in MATLAB (Mathworks, Natick, MA). Z-stacks for each 10X field were compiled and stacked to create a 3D image of the field. Initial position data for each field was extracted from the microscopy acquisition data and fields were stitched using rigid registration based on intensity correlation of the overlap between images. 3D point clouds were then constructed to represent the centroid position of the fluorescent beads using the binary image, and used to rigidly register each serial time point image to the initial time point using an iterative closest point algorithm. Uncommon z-planes between the time points due to physical microplate repositioning between imaging acquisitions were eliminated. To reduce dimensionality, maximum intensity projection images of the registered bead and MCTS images were used for subsequent image processing and analysis. MCTS pixel fluorescent intensity was normalized by identifying the peak intensity for the top 0.01% of pixels among all wells in the plate and across all time points, and normalizing each image to a scale of 0–1. This normalization defines the cell number carrying capacity for the model with the assumption of a linear relationship between fluorescent intensity and cell number. Regions-of-Interest (ROIs) for each MCTS were identified at each time point using a fully-automatic threshold-based segmentation method. Bead images were non-rigidly registered to the previous time point using multi-resolution free-field deformations based on multi-level B-splines to obtain the observed bead deformation field.

Biophysical model of MCTS growth and deformation. The biophysical MCTS growth model is based on previous work from our group developed at the in vivo clinical scale and modified for use at the in vitro MCTS scale. This study incorporates the same fundamental model used in our previous work with minimal modifications allowing for it to be used at the in vitro scale. The governing coupled partial differential equations are shown in Eqs. (1)–(3) below:

$$\frac{\partial N}{\partial t} = \nabla \cdot \left( D \nabla N(x, t) \right) + kN(x, t) \left( 1 - \frac{N(x, t)}{\theta} \right)$$  (1)

$$D = D_0 e^{-\gamma_{\text{s}} M(x,t)}$$  (2)

$$\nabla \cdot G \nabla \ddot{u} + \nabla \frac{G}{1 - 2v} \left( \nabla \cdot \ddot{u} \right) - \lambda \nabla N(x, t) = 0$$  (3)

Equation (1) models the rate of change of cell number, $N(x, t)$, at a given time and location as the sum of random cell diffusion and logistic growth, where $D (\mu m^2/h)$ is the local cellular diffusion coefficient of tumor cells in the presence of mechanical stress, $k (h^{-1})$ is the cell proliferation rate, and $\theta$ is the cell carrying capacity. Equation (2) couples Eq. (1) to the surrounding tissue stiffness and describes cell diffusion coefficient as a modification of the global cell diffusion coefficient, $D_0$, through distortional (von Mises) stress, $\sigma_{\text{M}}$, and an empirically derived coupling constant, $\lambda$. Equation (3) describes linear elastic, isotropic mechanical equilibrium with an external expansive force determined by changes in cell number and a biophysical traction force coefficient, $\lambda$, which governs the response of the displacement vector, $u$, to tumor cell growth. $G$ represents shear modulus and is defined as $G = E/(2(1 + \nu))$ where $E$ represents Young’s modulus and $\nu$ represents Poisson’s ratio. A uniform Young’s modulus of 2 kPa is assigned to the ECM, based on the assumption of uniform invasion matrix density throughout. In our previous work, the mechanical coupling constant, $\lambda$, was an empirically-derived coupling constant. In this work, model-to-data fitting of $\lambda$ is used to estimate the observed mechanical interactions in the MCTS system. The Young’s modulus of the spheroid core is unknown but assigned as an order of magnitude higher than the surrounding environment with the assumption that the spheroid core is stiffer than the collagen invasion matrix. We return to these assumptions in the Discussion section. Poisson’s ratio is assumed as 0.45 representing the near-incompressible nature of the hydrogel system and avoiding numerical instabilities due to incompressibility within a linear elastic model solution. Time stepping was assigned with $\Delta t = 0.125$ h for a duration of 12 h for each time point, for a total of 72 h (hour 96 to hour 24). Finite element meshes were constructed to represent the observed microscopy field of view domain and were composed of three-node triangular elements with an average edge length of 45 μm. The equations are solved using the Galerkin method of weighted residuals on triangular finite elements described by standard linear Lagrange basis functions using a fully explicit forward Euler method. We assume that the MCTS growth takes the form of a reaction diffusion logistic growth model, a commonly studied model for estimating the growth of tumors and avascular spheroids.

We utilize a first-order simplifying approximation by neglecting the convective velocity of cellular mitosis under the assumption that the time scale of tumor growth is sufficiently long such that convection motion driven by cell mitosis is minimal relative to diffusive motility.

Parameter estimation. Figure 2 shows the modeling approach for characterizing MCTS growth and mechanical interactions. A Levenberg–Marquardt least-squares non-linear optimization was used to estimate the proliferation rate ($k$), cellular diffusion coefficient ($D_0$), and the traction force coefficient ($\lambda$) between each imaging time point. Model parameters are assumed as piecewise continuous between each imaging time point over the observed time scale as linear uniform time invariant parameterization was determined as inadequate for characterizing MCTS systems. Modeling the changes between the observed time points allowed us to capture the dynamic changes of these biophysical parameters. Model parameters are assumed to be homogenous throughout the domain.
The objective function that was minimized is the sum-squared error between the observed and model-estimated spheroid cellularity, and the observed and model-estimated traction force displacement. Iterative parameter estimation was terminated based on the following convergence criteria: (a) absolute objective function value less than $1 \times 10^{-4}$, (b) relative change in the objective function between iterations less than $1 \times 10^{-2}$, (c) maximum of 500 iterations, or (d) maximum of 1,000 function evaluations. We note that relative objective function change was the typical convergence condition.

To improve inverse parameter optimization performance, we use an iterative sequential method to independently solve for the model parameters. Our sequential method involves solving the inverse problems in steps by fitting the model parameters between two sequential time points. Initially we use a cell number objective function to fit parameters of $D_0$ and $k$, with an arbitrary assigned $\lambda$. We then fit $\lambda$ using a displacement objective function holding the optimized first iteration $D_0$ and $k$ parameters fixed. We then repeat the process until the final model parameters are converged, which occurred in two iterations in all cases. In data not shown, we validated our parameter estimation methodology using synthetic in silico MCTS systems subjected over a dynamic range of parameters and found convergence of the inverse problem for parameter estimation to the correct set of parameters.

Spheroid ROIs and X and Y bead deformation at each time point were interpolated onto the mesh and used as inputs for the model. We derive a first-order approximation for spheroid cell density using a linear relationship between cell density and fluorescent intensity, with a maximal carrying capacity, $\Theta$, of 1 set from normalization of spheroid fluorescent intensity described above.
Results

Six MCTS systems (n = 3 untreated, n = 3 treated) were imaged and analyzed using our mathematical model. Figure 3 displays our data results for our model estimated biophysical parameters of cellular diffusion, cellular proliferation rate, and cellular traction force over the observed time course. Our mechanically-coupled reaction–diffusion model was capable of describing MCTS growth and traction force for both treated and untreated conditions. Figure 3 compares our model-estimated biophysical parameters to conventional morphometric techniques. Over time the MCTS core density is observed to reduce which we hypothesize is due to a combination of the diffusive motility (in which cells dissociate at a higher rate than proliferation) along with the avascular nature of the MCTS core. Imaging data and model predictions for MCTS systems from an untreated and treated representative MCTS systems are shown in Figs. 4, 5, 6 and 7. The mechanically-coupled reaction–diffusion model is used to estimate parameters of diffusion, proliferation rate, and mechanical traction forces by fitting the model to pairs of observational MCTS microscopy images. The model-based parameters are used to characterize untreated and treated MCTS systems to distinguish between the two groups. Figures 4 and 5 display and compare cellular density observation and model-estimated data over the imaging time course for representative untreated and treated MCTS systems. Qualitatively, the untreated MCTS systems show cellular invasion into the surrounding microenvironment whereas as compared to hindered cellular invasion in the treated MCTS systems. Compared to observed cellularity data, our model underestimates MCTS core cellularity once cellular invasion into the ECM begins. Figures 6 and 7 display and compare X and Y deformation observation and model-estimated data over the imaging time course from representative untreated and treated MCTS systems. As expected, we observe more deformation in untreated MCTS systems compared to treated MCTS systems. In both untreated and treated MCTS systems, peak deformation is observed adjacent to the MCTS edge with a reduction in deformation in the radial direction. We also observe the bulk of deformation changes during the earlier time points over the imaging time course with the differences in deformation minimizing in later time points. The bead deformation field image is obtained through non-rigid registration of fluorescent bead images, and the model is used to estimate $\lambda$, to characterize the underlying biophysics of cell-ECM mechanical interactions. Qualitatively, the treated MCTS deformation field map exhibits a significant decrease in bead displacement relative to untreated MCTS. Statistical analysis was performed to determine the ability of the model to characterize treatment effects on MCTS systems using biophysical parameters. An unpaired parametric $t$-test was used for each parameter at each time point with a significance level, alpha of 0.05. The mean, standard deviation and statistical significance for each parameter are reported in Table 1. As shown in Table 1, the model was able to characterize treatment-induced differences in MCTS growth and mechanical interaction biophysical parameters over the time course.

Our results show promise in describing MCTS systems using $D_0$, $k$, and $\lambda$. To compare our biophysical model-based biomarker analysis to conventional MCTS analysis we assessed conventional morphometric analysis of core and invasive diameter. We defined the core diameter using the maximum intensity projection image at the initial time point with a threshold selected for fluorescent intensity to define the core diameter. The longest dimension of the total MCTS ROI was defined as the invasive diameter. Figure 3 shows model estimated biophysical parameters and the conventional morphometric analysis over the observed time course. We found that the core
Figure 4. Observational microscopy images, model characterization of cellular density, and error maps between the observed and model-estimated cellular density for one representative untreated MCTS system is shown. Processed observational microscopy images show cellular density on a scale from 0 to 1. Cellular density is estimated using our computational model and is used to estimate parameters of cellular diffusion and proliferation between each imaging time point. Error maps show model-data misfit of cellular density.

Figure 5. Observational microscopy images, model characterization of cellular density, and error maps between the observed and model-estimated cellular density for one representative treated MCTS system is shown. Processed observational microscopy images show cellular density on a scale from 0 to 1. Cellular density is estimated using our computational model and is used to estimate parameters of cellular diffusion and proliferation between each imaging time point. Error maps show model-data misfit of cellular density.
diameter was not able to differentiate between treated and untreated conditions with no significant differences throughout the treatment time course. The traditional morphologic measurement of invasive diameter was able to distinguish between the treated and untreated MCTS systems, but is only statistically significant following 48 h of growth and invasion. Comparatively, the combination of our model fit parameters $D_0$, $k$, and $\lambda$ better characterize the biophysical changes between untreated and treated MCTS systems with increased sensitivity throughout the entire time course.

Discussion
In this work, we modified our previously published mechanically-coupled reaction–diffusion model by extension from the in vivo clinical scale to describe in vitro MCTS growth, invasion, and mechanical interaction within extracellular matrix. We show that biophysical model parameters of cell diffusion, proliferation, and cellular traction force can be reliably estimated from observational microscopy imaging of MCTS growth and mechanical interactions. These model-based quantitative biomarkers indicate the underlying biophysics driving growth and invasion into the surrounding ECM and reveal important biological insights through the use of observational imaging data alone. Importantly, the model-based framework was able to distinguish between treated and untreated MCTS systems, validating that our modeling framework is able to characterize both growth and treatment-related parameters. We found significant differences in model parameters of diffusion, proliferation, and cellular traction force between untreated and treated MCTS spheroids. In this study, we use the antineoplastic therapeutic nab-paclitaxel, a taxane-based chemotherapeutic antimicrotubule agent. Taxanes stabilize microtubules against depolymerization, blocking the cell cycle in G1 or M phases and preventing cell division and triggering cell cycle arrest and mitotic catastrophe. This results in reduced proliferation, which is reflected in our modeling framework through significantly lower proliferation rates observed for treated MCTS systems. Further, microtubule cytoskeletal networks are crucial for transducing and regulating mechanical signals, with cellular traction force generated through microtubule depolymerization. This mechanism is reflected in our modeling framework through significant attenuation in the traction force parameter at early time points. At the later time points, there is a significant reduction in the amount of cellular traction force which may be an effect
of the ECM stiffening. In untreated MCTS systems, we see a substantial amount of initial traction force, but the traction force is significantly lower in MCTS systems treated with nab-paclitaxel. The mechanistic validation of our modeling framework through the use of a widely-studied antineoplastic agent with well-characterized mechanisms of action provides significant promise for the use of our model to characterize biophysical mechanistic treatment effects.

Here, we show characterization of the dynamic changes in mechanistic biophysical properties that enhances the available information from traditional drug sensitivity assays without requiring significant changes to current observational imaging protocols. In the current state of conventional drug sensitivity screening, morphometric measurements and cell counts reflect the eventual downstream consequences of treatment (cytostatic or cytotoxic

**Figure 7.** The model characterization of cellular traction force for one representative treated MCTS system is shown. X and Y deformation field images are determined based on non-rigid registration of observational microscopy imaging of fluorescent microbeads over time. Using the model-fit cellular density parameters and observational deformation field images in combination with our computational model, a cellular traction force parameter is estimated between each imaging time point. The figure reflects the cumulative cellular traction force overtime in both X and Y displacement directions. Error maps show the model-data misfit for both X and Y deformation.

| Time point (hours) | Diffusion | Proliferation | Traction force |
|-------------------|-----------|---------------|---------------|
|                   | Untreated | Treated       | Untreated     | Treated     |
| 36                | 399.46 ± 31.99 | 95.79 ± 29.36*** | 1.18E−2 ± 1.73E−3 | 3.37E−3 ± 3.07E−3* |
| 48                | 352.7 ± 43.77    | 81.73 ± 44.57*** | 1.12E−2 ± 3.52E−3 | 6.69E−3 ± 2.21E−3 |
| 60                | 256.72 ± 41.08 | 57.33 ± 48.54*  | 1.01E−2 ± 1.28E−3 | 4.96E−3 ± 2.12E−3 |
| 72                | 248.27 ± 43.78 | 56.67 ± 45.43** | 9.5E−3 ± 1.14E−3 | 4.18E−3 ± 1.47E−3* |
| 84                | 243.17 ± 36.16 | 52.84 ± 47.09** | 1.02E−2 ± 5.95E−4 | 3.20E−3 ± 1.50E−3* |
| 96                | 219.83 ± 36.91 | 19.87 ± 7.15**  | 8.45E−3 ± 8.64E−4 | 3.20E−4 ± 4.53E−4*** |

Table 1. Mean and standard deviations for each model parameter and time point. *Denotes statistical significance with \( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \).
effects) but obfuscates the underlying mechanisms that are driving observed tumor growth and therapeutic responses. While we show that conventional assessment methods (e.g. spheroid core and invasive diameter) may eventually yield statistically significant changes in response to treatment that reflects observable cytotoxic effects, biophysical characterization methods as developed in this study provide advantages in providing mechanistic insight. The spheroid core diameter was unable to distinguish between the treated and untreated MCTS systems throughout the entire time course. The core diameter also showed a slight reduction in MCTS cell density over the time course which we hypothesize could be due to diffusive motility and the avascular nature of MCTS systems. Due to the mechanical invasion motility process, cells dissociate from the MCTS core at a faster rate than they are proliferating leading to a slight core reduction. Additionally, as the MCTS systems are an avascular system, the internal cells of the MCTS core may receive restricted oxygen and nutrient penetration potentially leading to cellular senescence and/or apoptosis. The spheroid invasive diameter was able to distinguish between the treated and untreated MCTS systems at later time points, however mechanistic interpretation is limited with failure to describe the underlying biophysics which drive these observed morphometric changes.

While the results of this study are promising, there are several limitations. In our model we assumed homogeneous mechanical stiffness throughout the extracellular matrix domain with the heterogeneity of collagen matrix stiffness not considered in this work. Cancer cells have been shown to induce ECM remodeling through deposition, crosslinking, and alignment of ECM collagen fibers which is known to stiffen the ECM, however accurate methods to quantify the bulk heterogeneity of mechanical stiffness in ECM in vitro systems are challenging. It would be of interest to develop methods to quantify stiffness throughout MCTS systems over time. By incorporating more accurate mechanical stiffness assumptions, we could improve our spatiotemporal model fits. Incorporating this heterogeneity would increase the complexity of the proposed model, requiring additional experimental data to characterize the stiffness. Additionally, in this work, we only characterize the MCTS systems using 2D analysis. While acquired images are 3D, in this first-order analysis we dimensionally-reduced our input data to 2D in order to simplify the initial validation of our modeling framework to describe biophysical changes in response to treatment. With further model development, in future studies we will characterize these biophysical parameters in 3D. Despite these limitations, our model allowed for the mechanistic characterization of biophysical changes in MCTS systems, improving upon current conventional morphometric assessment methods.

While in this work we restricted our analysis to biophysical parameters of proliferation, diffusion, and traction forces, this mathematical analysis framework is generalizable and has the ability to be extended to evaluate additional biophysical phenomena. Our model has the potential to additionally account for other phenotypic biophysical TME factors affecting growth and therapeutic response, including the addition of active migration/motility through haptotaxis along stiffness gradients, cellular metabolism regulated by spatial oxygen gradients, and collagen fiber remodeling and alignment. Our methodology also shows promise in the ability to describe cell population-specific and drug-specific biophysics by evaluating various breast cancer cell lines and therapeutic agents. Our modeling framework may also be applied to assessment of 3D breast cancer organoid models using patient-derived cells. Characterizing mechanistic biophysical parameters could enable patient-specific therapeutic selection by identifying patient-specific biophysical phenomena driving tumor growth or reflecting particular therapeutic vulnerabilities.

This integration of microscopy imaging, biophysics, and mathematical modeling has the potential to impact many areas of research pertaining to dynamics of cancer growth and therapeutic response including cell line observations, drug sensitivity assays, anti-cancer drug development, and patient-specific drug selection and prediction of response. Ultimately, pre-existing cellular biophysics dictates individual phenotypic observations of cancer growth and response to therapy; yet conventional microscopy imaging assessment methods are relegated to monitoring the conclusions of these phenotypic responses and not their underlying causes. The coarseness of these outcome measures complicates efforts to understand the mechanistic effects of drugs or the specific driving biological factors in patient-derived samples as many different combinations and levels of various biophysical phenomena may yield similar final observed responses. In this work, we demonstrate the utility of a microscopy imaging-data driven modeling approach to quantify cellular biophysics based on fitting longitudinal observations to biophysical models in an important step towards precision evaluation.

Received: 12 February 2020; Accepted: 23 June 2020
Published online: 14 July 2020

References
1. El Hachem, G., Gombos, A. & Awada, A. Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. F1000Research 8 (2019).
2. Kratz, J. et al. Incorporating genomics into the care of patients with advanced breast cancer. Am. Soc. Clin. Oncol. Educ. Book 38, 36–64 (2018).
3. Higgins, M. J. & Baselga, J. Targeted therapies for breast cancer. J. Clin. Invest. 121, 3797–3803 (2011).
4. Goutelle, S. et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam. Clin. Pharmacol. 22, 633–648 (2008).
5. Pampaloni, F., Reynaud, E. G. & Stelzer, E. H. K. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8, 839–845 (2007).
6. Johnson, J. L. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
7. Breslin, S. & O’Driscoll, L. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget 7, 45745–45756 (2016).
8. Hutchinson, L. & Kirk, R. High drug attrition rates—where are we going wrong?. Nat. Rev. Clin. Oncol. 8, 189–190 (2011).
9. Antoni, D., Burckel, H., Josset, E. & Noel, G. Three-dimensional cell culture: a breakthrough in vivo. *Int. J. Mol. Sci.* **16**, 5517–5527 (2015).
10. Saleh, F. A. & Genever, P. G. Turning round: multipotent stromal cells, a three-dimensional revolution?. *Cytoteraphy* **13**, 903–912 (2011).
11. Lee, J., Cuddihy, M. J. & Kotov, N. A. Three-dimensional cell culture matrices: state of the art. *Tissue Eng. Part B Rev.* **14**, 61–86 (2008).
12. Charoen, K. M., Fallica, B., Colson, Y. L., Zaman, M. H. & Grinstaff, M. W. Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations. *Biomaterials* **35**, 2264–2271 (2014).
13. Loesener, D. *et al.* Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. *Biomaterials* **31**, 8494–8506 (2010).
14. Vinci, M. *et al.* Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. *BMC Biol.* **10**, 29 (2012).
15. Northcott, J. M., Dean, I. S., Mouw, J. K. & Weaver, V. M. Feeling stress: the mechanics of cancer progression and aggression. *Front. Cell Dev. Biol.* **6**, 17 (2018).
16. Kraning-Rush, C. M., Califano, J. P. & Reinhart-King, C. A. Cellular traction stresses increase with increasing metastatic potential. *PLoS ONE* **7**(2), e32572 (2012).
17. Lazzari, G., Couvreur, P. & Mura, S. Multicellular tumor spheroids: a relevant 3D model for the in vitro preclinical investment of polymer nanomedicines. *Polym. Chem.* **8**, 4947–4969 (2017).
18. Seymour, L. *et al.* iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol.* **18**, e143–e152 (2017).
19. Tsuchiada, Y. & Therasse, P. Response evaluation criteria in solid tumors (RECIST): new guidelines. *Med. Pediatr. Oncol.* **37**, 1–3 (2001).
20. Stein, A. M., Demuth, T., Mobley, D., Reners, M. & Sander, L. M. A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment. *Biophys. J.* **92**, 356–365 (2007).
21. Byrne, H. M. Dissecting cancer through mathematics: from the cell to the animal model. *Nat. Rev. Cancer* **10**, 221–230 (2010).
22. Lal-Nag, M. *et al.* Exploring drug dosing regimens in vitro using real-time 3D spheroid tumor growth assays. *SLAS Discov. Adv. Life Sci. R&D** **22**, 537–546 (2017).
23. Wallace, D. I. & Guo, X. Properties of tumor spheroid growth exhibited by simple mathematical models. *Front. Oncol.* **3**, 51 (2013).
24. Weis, J. A., Miga, M. I. & Yankelev, T. E. Three-dimensional image-based mechanical modeling for predicting the response of breast cancer to neoadjuvant therapy. *Comput. Methods Appl. Mech. Eng.* **314**, 494–512 (2017).
25. Narasimhan, S. *et al.* Biophysical model-based parameters to classify tumor recurrence from radiation-induced necrosis for brain metastases. *Med. Phys.* **46**(5), 2487–2496 (2019).
26. Weis, J. A. *et al.* Predicting the response of breast cancer to neoadjuvant therapy using a mechanically coupled reaction–diffusion model. *Cancer Res.* **75**(22), 4697–4707 (2015).
27. Weis, J. A. *et al.* A mechanically coupled reaction-diffusion model for predicting the response of breast tumors to neoadjuvant chemotherapy. *Phys. Med. Biol.* **58**, 5851–5866 (2013).
28. Lima, E. A. B. F. *et al.* Calibration of multi-parameter models of avascular tumor growth using real time resolved microscopy data. *Sci. Rep.* **8**, 14558 (2018).
29. Kumar, K. V. & Hema, K. N. Tumor cell interactions with the extracellular matrix during invasion and metastasis. *J. Oral Maxillofac. Patiol.* **23**(1), 10–16 (2019).
30. Bloom, R. J., George, I. P., Celedon, A., Sun, S. X. & Wirtz, D. Mapping local matrix remodeling induced by a migrating tumor cell using three-dimensional multiple particle tracking. *Biophys. J.* **95**, 4077–4088 (2008).
31. Kopanska, K. S., Alcheikh, Y., Staneva, R., Vignjevic, D. & Betz, T. Tensile forces originating from cancer spheroids facilitate tumor invasion. *PLoS ONE* **11**, e0156442 (2016).
32. Malandrino, A., Mak, M., Kamm, R. D. & Moeendarbary, E. Complex mechanics of the heterogeneous extracellular matrix in cancer. *Extreme Mech. Lett.* **21**, 25–34 (2018).
33. Kopanska, K. S. *et al.* Quantification of collagen contraction in three-dimensional cell culture. *Methods Cell Biol.* **125**, 353–372 (2015).
34. Froehlich, K. *et al.* Generation of multicellular breast cancer tumor spheroids: comparison of different protocols. *J. Mammary Gland Biol. Neoplasia* **21**(1), 89–96 (2016).
35. Schnabel, J.A., Rueckert, D., Quist, M., Clackall, J.M., Castellano-Smith, A.D., Hartkens, T., Penney, G.P., Hall, W.A., Liu, H., Truwit, C.L., Gerritsen, F.A., Hill, D.L.G., Hawkes, D.J. A generic framework for non-rigid registration based on non-uniform multi-level free-form deformations. In *Medical Image Computing and Computer-Assisted Intervention—MICCAI 2001*, Vol. 2208, 573–581 (2001).
36. Klein, S., Staring, M., Murphy, K., Viergever, M. A. & Pluim, J. P. W. elastix: a toolbox for intensity-based medical image registration. *IEEE Trans. Med. Imaging* **29**, 196–205 (2010).
37. Arnal, I. & Wade, R. H. How does taxol stabilize microtubules?: *Carr. Biol.* **5**, 900–908 (1995).
38. Rape, A., Guo, W. & Wang, Y. Microtubule depolymerization induces traction force increase through two distinct pathways. *J. Cell Sci.* **124**, 4233–4240 (2011).

**Acknowledgements**
National Institutes of Health – National Cancer Institute K25CA204599 and P30CA012197. Wake Forest Baptist Medical Center Comprehensive Cancer Center Signaling and Biotechnology Program Pilot Grant.

**Author contributions**
H.J.B. and J.A.W. conceived the experiments. H.J.B. and E.E.F. conducted the experiments under the guidance of J.A.W. and A.T. H.J.B. and J.A.W. analyzed results. All authors reviewed the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-68324-4.

**Correspondence** and requests for materials should be addressed to J.A.W.

**Reprints and permissions information** is available at www.nature.com/reprints.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020